Diagnosis and treatment of chordoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 6, 2013, Pages 726-731

  Williams, Brian J ^a   Raper, Daniel M S ^a   Godbout, Erin ^a   David Bourne, T ^a   Prevedello, Daniel M ^b   Kassam, Amin B ^c   Park, Deric M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ALKYLATING AGENT; ANTHRACYCLINE; CISPLATIN;

ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CHORDOMA; CLINICAL FEATURE; HUMAN; PATHOGENESIS; PREVALENCE;

EID: 84879329018     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0089     Document Type: Article

References (51)

1. Healey JH, Lane JM. Chordoma: a critical review of diagnosis and treatment. Orthop Clin North Am 1989;20:417-426. (Pubitemid 19168023)
2. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001;12:1-11. (Pubitemid 32125896)
3. Cheng EY, Ozerdemoglu RA, Transfeldt EE, et al. Lumbosacral chordoma. Prognostic factors and treatment. Spine (Phila Pa 1976) 1999;24:1639-1645. (Pubitemid 29387919)
4. Virchow R. Untersuchungen ueber die Entwicklung des Schaedelgrundes. Berlin: G Rimer; 1857.
5. Ribbert H. Uber die Ecchondosis phsaliphora sphenooccipitalis. Zentralbl Allg Path 1894;5:457-461.
6. Salisbury JR. The pathology of the human notochord. J Pathol 1993;171:253-255. (Pubitemid 24022985)
7. Choi KS, Cohn MJ, Harfe BD. Identification of nucleus pulposus precursor cells and notochordal remnants in the mouse: implications for disk degeneration and chordoma formation Dev Dyn 2008;237:3953-3958.
8. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006;209:157-165. (Pubitemid 43805410)
9. Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Mod Pathol 2008;21:1461-1469.
10. Yang XR, Ng D, Alcorta DA, et al. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 2009;41:1176-1178.
11. Hallor KH, Staaf J, Jonsson G, et al. Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridization. Br J Cancer 2008;98:434-442. (Pubitemid 351161241)
12. Tamborini E, Miselli F, Negri T, et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006;12:6920-6928. (Pubitemid 44974484)
13. Han S, Polizzano C, Nielsen GP, et al. Aberrant hyperactivation of akt and mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res 2009;15:1940-1946.
14. Deniz ML, Kilic T, Almaata I, et al. Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence. Neurosurgery 2002;51:753-760; discussion 760. (Pubitemid 36331070)
15. Boriani S, Chevalley F, Weinstein JN, et al. Chordoma of the spine above the sacrum. Treatment and outcome in 21 cases. Spine (Phila Pa 1976) 1996;21:1569-1577.
16. Bjornsson J, Wold LE, Ebersold MJ, et al. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer 1993;71:735-740. (Pubitemid 23051375)
17. Gagliardi F, Boari N, Riva P, et al. Current therapeutic options and novel molecular markers in skull base chordomas. Neurosurg Rev 2012;35:1-13; discussion 13-14.
18. Fourney DR, Gokaslan ZL. Current management of sacral chordoma. Neurosurg Focus 2003;15:E9.
19. Bergh P, Kindblom LG, Gunterberg B, et al. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 2000;88:2122-2134. (Pubitemid 30233215)
20. Walcott BP, Nahed BV, Mohyeldin A, et al. Chordoma: current concepts, management, and future directions. Lancet Oncol 2012;13:e69-e76.
21. Maclean FM, Soo MY, Ng T. Chordoma: radiological-pathological correlation. Australas Radiol 2005;49:261-268. (Pubitemid 41097961)
22. Rossleigh MA, Smith J, Yeh SD. Scintigraphic features of primary sacral tumors. J Nucl Med 1986;27:627-630.
23. Park SA, Kim HS. F-18 FDG PET/CT evaluation of sacrococcygeal chordoma. Clin Nucl Med 2008;33:906-908.
24. Gray SW, Singhabhandhu B, Smith RA, et al. Sacrococcygeal chordoma: report of a case and review of the literature. Surgery 1975;78:573-582.
25. Arnautovic KI, Al-Mefty O. Surgical seeding of chordomas. J Neurosurg 2001;95:798-803. (Pubitemid 33043353)
26. Chugh R, Tawbi H, Lucas DR, et al. Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007;12:1344-1350. (Pubitemid 350232608)
27. Crapanzano JP, Ali SZ, Ginsberg MS, et al. Chordoma: a cytologic study with histologic and radiologic correlation. Cancer 2001;93:40-51.
28. Holton JL, Steel T, Luxsuwong M, et al. Skull base chordomas: correlation of tumour doubling time with age, mitosis and Ki67 proliferation index. Neuropathol Appl Neurobiol 2000;26:497-503. (Pubitemid 32049848)
29. Stener B, Gunterberg B. High amputation of the sacrum for extirpation of tumors. Principles and technique. Spine (Phila Pa 1976) 1978;3:351-366.
30. Kaiser TE, Pritchard DJ, Unni KK. Clinicopathologic study of sacrococcygeal chordoma. Cancer 1984;53:2574-2578. (Pubitemid 14102506)
31. Fuchs B, Dickey ID, Yaszemski MJ, et al. Operative management of sacral chordoma J Bone Joint Surg Am 2005;87:2211-2216. (Pubitemid 41407545)
32. Samson IR, Springfield DS, Suit HD, et al. Operative treatment of sacrococcygeal chordoma. A review of twenty-one cases. J Bone Joint Surg Am 1993;75:1476-1484. (Pubitemid 23358235)
33. Stuer C, Schramm J, Schaller C. Skull base chordomas: management and results. Neurol Med Chir (Tokyo) 2006;46:118-124; discussion 124-125.
34. Catton C, O'Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 1996;41:67- 72.
35. Noel G, Feuvret L, Calugaru V, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol 2005;44:700-708. (Pubitemid 41547070)
36. Park L, Delaney TF, Liebsch NJ, et al. Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006;65:1514-1521. (Pubitemid 44425209)
37. Kano H, Iqbal FO, Sheehan J, et al. Stereotactic radiosurgery for chordoma: a report from the North American Gamma Knife Consortium. Neurosurgery 2011;68:379-389.
38. Gupta T, Wadasadawala T, Master Z, et al. Encouraging early clinical outcomes with helical tomotherapy-based image-guided intensity-modulated radiation therapy for residual, recurrent, and/or progressive benign/low-grade intracranial tumors: a comprehensive evaluation. Int J Radiat Oncol Biol Phys 2012;82:756-764.
39. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009;74:732-739.
40. Chugh R, Dunn R, Zalupski MM, et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 2005;23:3597-3604.
41. Fleming GF, Heimann PS, Stephens JK, et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 1993;72:714-718. (Pubitemid 23215255)
42. Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol 2012;30:914-920.
43. Negri T, Casieri P, Miselli F, et al. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. Br J Cancer 2007;96:180-181. (Pubitemid 46094661)
44. Stacchiotti S, Marrari A, Tamborini E, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 2009;20:1886- 1894.
45. Yang C, Schwab JH, Schoenfeld AJ, et al. A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther 2009;8:2597-2605.
46. Yang C, Hornicek FJ, Wood KB, et al. Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. Spine (Phila Pa 1976) 2010;35:1668-1675.
47. Hsu W, Mohyeldin A, Shah SR, et al. Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. J Neurosurg 2011;115:760-769.
48. Fernando RI, Litzinger M, Trono P, et al. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 2010;120:533-544.
49. Presneau N, Shalaby A, Ye H, et al. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol 2011;223:327-335.
50. Liu X, Nielsen GP, Rosenberg AE, et al. Establishment and characterization of a novel chordoma cell line: CH22. J Orthop Res 2012;30:1666-1673.
51. Siu IM, Salmasi V, Orr BA, et al. Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg 2012;116:801-809.